Observational Study for Left Main Disease Treatment

Conditions

Coronary Artery Disease

Keywords

Left Main

Brief summary

The purpose of this study is to observe clinical courses for long-term in patients with unprotected LMCA disease and to evaluate comparative results of medical treatment, coronary stenting with drug-eluting stents, and CABG for the treatment of an unprotected LMCA stenosis in the "real world" daily practice.

Detailed description

This study is a multicenter, large clinical registry to evaluate comparative outcomes of medical therapy, PCI with DES, or CABG for patients with unprotected LMCA stenosis in the Asia-Pacific, as recorded in the MAIN-IRIS Registry. Data will be prospectively collected on approximately 5000 subjects who diagnosed LM disease (\>50% by visual estimation) at approximately 65 centers in Korea and Asia-Pacific region. Brief study design is as depicted in the following figure

Kim TO, Kang DY, Ahn JM, Kim MJ, Lee PH, Kim H, Choi Y, Lee J, Lee JM, Jo HH, Park YS, Lim SM, Park SJ, Park DW.

2024-01-014 citations

10.1016/j.jcin.2023.10.068

Dual antiplatelet therapy after percutaneous coronary intervention for left main coronary artery disease.

Cho S, Kang DY, Kim JS, Park DW, Kim IS, Kang TS, Ahn JM, Lee PH, Kang SJ, Lee SW, Kim YH, Lee CW, Park SW, Lee SJ, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Jang Y, Hong MK, Park SJ.

2022-07-275 citations

10.1016/j.rec.2022.07.007

Revascularization in Patients With Left Main Coronary Artery Disease and Left Ventricular Dysfunction.

Park S, Ahn JM, Kim TO, Park H, Kang DY, Lee PH, Jeong YJ, Hyun J, Lee J, Kim JH, Yang Y, Choe K, Park SJ, Park DW, IRIS-MAIN Registry Investigators.

2020-09-0127 citations

10.1016/j.jacc.2020.07.047

Differential Event Rates and Independent Predictors of Long-Term Major Cardiovascular Events and Death in 5795 Patients With Unprotected Left Main Coronary Artery Disease Treated With Stents, Bypass Surgery, or Medication

Se Hun Kang, Jung‐Min Ahn, Cheol Hyun Lee, Pil Hyung Lee, Soo‐Jin Kang et al. (11 authors)

Circulation Cardiovascular Interventions2017-07-0125 citations

10.1161/circinterventions.116.004988

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Significant unprotected left main stenosis (\>50% by visual estimation) * The LMCA is considered unprotected if there are no patent coronary artery bypass grafts to the left anterior descending artery or the left circumflex artery. * No limitation of clinical or lesion characteristics * Age \>18 years * The patient or guardian agrees to the study protocol and the schedule of clinical follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethics Committee of the respective clinical site.

Exclusion criteria

* Protected left main stenosis

Design outcomes

Primary

Measure	Time frame	Description
Composite event rate of death, myocardial infarction, Target Vessel Revascularization or cerebrovascular event	2-year	A composite endpoint is an endpoint that is a combination of multiple clinical endpoints. An event that is considered to have occurred if any one of several different events is observed.

Secondary

Measure	Time frame	Description
Death	10-year	—
Cardiac death	10-year	—
Myocardial infarction	10-year	—
Cerebrovascular event	10-year	—
Target vessel revascularization	10-year	—
Target lesion revascularization	10-year	—
Stent thrombosis	10-year	According to Academic Research Consortium (ARC) criteria
Binary restenosis and late luminal loss in both in-stent and in-segment	9-month	Angiographic follow-up in the PCI group (as form of PCI substudy)
Rehospitalization	10-year	—

Countries

China, Malaysia, South Korea, Taiwan, Thailand

Contacts

CONTACTSeung-Jung Park, MD, PhD

sjpark@amc.seoul.kr82-2-3010-3152

PRINCIPAL_INVESTIGATORSeung-Jung Park, MD, PhD

CVRF

Outcome results